In particular, HER2 status is a known prognostic and predictive factor with a more aggressive tumour biology but with an increased survival associated with anti-HER2 therapy [8] and the lack of this information complicates the interpretation of the OS results in current clinical practice. This evidence concerns the gene ERBB2 and neoplasm.